TY - JOUR AU - Shankland, K. R. AU - Armitage, J. O. AU - Hancock, B. W. PY - 2012 DA - 2012// TI - Non-Hodgkin lymphoma JO - Lancet VL - 380 UR - https://doi.org/10.1016/S0140-6736(12)60605-9 DO - 10.1016/S0140-6736(12)60605-9 ID - Shankland2012 ER - TY - JOUR AU - Honigberg, L. A. AU - Smith, A. M. AU - Sirisawad, M. AU - Verner, E. AU - Loury, D. AU - Chang, B. AU - Li, S. AU - Pan, Z. AU - Thamm, D. H. AU - Miller, R. A. PY - 2010 DA - 2010// TI - The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy JO - Proc Natl Acad Sci U S A VL - 107 UR - https://doi.org/10.1073/pnas.1004594107 DO - 10.1073/pnas.1004594107 ID - Honigberg2010 ER - TY - JOUR AU - Wang, M. L. AU - Rule, S. AU - Martin, P. AU - Goy, A. AU - Auer, R. AU - Kahl, B. S. AU - Jurczak, W. AU - Advani, R. H. AU - Romaguera, J. E. AU - Williams, M. E. PY - 2013 DA - 2013// TI - Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma JO - N Engl J Med VL - 369 UR - https://doi.org/10.1056/NEJMoa1306220 DO - 10.1056/NEJMoa1306220 ID - Wang2013 ER - TY - JOUR AU - Hu, S. AU - Xu-Monette, Z. Y. AU - Tzankov, A. AU - Green, T. AU - Wu, L. AU - Balasubramanyam, A. AU - Liu, W. M. AU - Visco, C. AU - Li, Y. AU - Miranda, R. N. PY - 2013 DA - 2013// TI - MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from the international DLBCL rituximab-CHOP consortium program JO - Blood VL - 121 UR - https://doi.org/10.1182/blood-2012-10-460063 DO - 10.1182/blood-2012-10-460063 ID - Hu2013 ER - TY - JOUR AU - Visco, C. AU - Tzankov, A. AU - Xu-Monette, Z. Y. AU - Miranda, R. N. AU - Tai, Y. C. AU - Li, Y. AU - Liu, W. M. AU - d'Amore, E. S. AU - Li, Y. AU - Montes-Moreno, S. PY - 2013 DA - 2013// TI - Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an international DLBCL rituximab-CHOP consortium program study JO - Haematologica VL - 98 UR - https://doi.org/10.3324/haematol.2012.066209 DO - 10.3324/haematol.2012.066209 ID - Visco2013 ER - TY - JOUR AU - Thieblemont, C. AU - Briere, J. PY - 2013 DA - 2013// TI - MYC, BCL2, BCL6 in DLBCL: impact for clinics in the future? JO - Blood VL - 121 UR - https://doi.org/10.1182/blood-2013-01-480392 DO - 10.1182/blood-2013-01-480392 ID - Thieblemont2013 ER - TY - JOUR AU - Cheah, C. Y. AU - Seymour, J. F. AU - Wang, M. L. PY - 2016 DA - 2016// TI - Mantle cell lymphoma JO - J Clin Oncol Off J Am Soc Clin Oncol VL - 34 UR - https://doi.org/10.1200/JCO.2015.63.5904 DO - 10.1200/JCO.2015.63.5904 ID - Cheah2016 ER - TY - JOUR AU - O'Connor, O. A. PY - 2005 DA - 2005// TI - Marked clinical activity of the proteasome inhibitor bortezomib in patients with follicular and mantle-cell lymphoma JO - Clin Lymphoma Myeloma VL - 6 UR - https://doi.org/10.3816/CLM.2005.n.046 DO - 10.3816/CLM.2005.n.046 ID - O'Connor2005 ER - TY - JOUR AU - Bose, P. AU - Batalo, M. S. AU - Holkova, B. AU - Grant, S. PY - 2014 DA - 2014// TI - Bortezomib for the treatment of non-Hodgkin's lymphoma JO - Expert Opin Pharmacother VL - 15 UR - https://doi.org/10.1517/14656566.2014.965142 DO - 10.1517/14656566.2014.965142 ID - Bose2014 ER - TY - JOUR AU - Leonard, J. P. AU - Kolibaba, K. S. AU - Reeves, J. A. AU - Tulpule, A. AU - Flinn, I. W. AU - Kolevska, T. AU - Robles, R. AU - Flowers, C. R. AU - Collins, R. AU - DiBella, N. J. PY - 2017 DA - 2017// TI - Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma JO - J Clin Oncol Off J Am Soc Clin Oncol VL - 35 UR - https://doi.org/10.1200/JCO.2017.73.2784 DO - 10.1200/JCO.2017.73.2784 ID - Leonard2017 ER - TY - JOUR AU - Nencioni, A. AU - Hua, F. AU - Dillon, C. P. AU - Yokoo, R. AU - Scheiermann, C. AU - Cardone, M. H. AU - Barbieri, E. AU - Rocco, I. AU - Garuti, A. AU - Wesselborg, S. PY - 2005 DA - 2005// TI - Evidence for a protective role of mcl-1 in proteasome inhibitor-induced apoptosis JO - Blood VL - 105 UR - https://doi.org/10.1182/blood-2004-10-3984 DO - 10.1182/blood-2004-10-3984 ID - Nencioni2005 ER - TY - JOUR AU - Chen, R. AU - Guo, L. AU - Chen, Y. AU - Jiang, Y. AU - Wierda, W. G. AU - Plunkett, W. PY - 2011 DA - 2011// TI - Homoharringtonine reduced mcl-1 expression and induced apoptosis in chronic lymphocytic leukemia JO - Blood VL - 117 UR - https://doi.org/10.1182/blood-2010-01-262808 DO - 10.1182/blood-2010-01-262808 ID - Chen2011 ER - TY - JOUR AU - Gandhi, V. AU - Plunkett, W. AU - Cortes, J. E. PY - 2014 DA - 2014// TI - Omacetaxine: a protein translation inhibitor for treatment of chronic myelogenous leukemia JO - Clin Can Res VL - 20 UR - https://doi.org/10.1158/1078-0432.CCR-13-1283 DO - 10.1158/1078-0432.CCR-13-1283 ID - Gandhi2014 ER - TY - JOUR AU - Quintas-Cardama, A. AU - Kantarjian, H. AU - Cortes, J. PY - 2009 DA - 2009// TI - Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009 JO - Cancer VL - 115 UR - https://doi.org/10.1002/cncr.24601 DO - 10.1002/cncr.24601 ID - Quintas-Cardama2009 ER - TY - JOUR AU - Alvandi, F. AU - Kwitkowski, V. E. AU - Ko, C. W. AU - Rothmann, M. D. AU - Ricci, S. AU - Saber, H. AU - Ghosh, D. AU - Brown, J. AU - Pfeiler, E. AU - Chikhale, E. PY - 2014 DA - 2014// TI - U.S. Food and Drug Administration approval summary: omacetaxine mepesuccinate as treatment for chronic myeloid leukemia JO - Oncologist VL - 19 UR - https://doi.org/10.1634/theoncologist.2013-0077 DO - 10.1634/theoncologist.2013-0077 ID - Alvandi2014 ER - TY - JOUR AU - Allan, E. K. AU - Holyoake, T. L. AU - Craig, A. R. AU - Jorgensen, H. G. PY - 2011 DA - 2011// TI - Omacetaxine may have a role in chronic myeloid leukaemia eradication through downregulation of mcl-1 and induction of apoptosis in stem/progenitor cells JO - Leukemia VL - 25 UR - https://doi.org/10.1038/leu.2011.55 DO - 10.1038/leu.2011.55 ID - Allan2011 ER - TY - JOUR AU - Kuroda, J. AU - Kamitsuji, Y. AU - Kimura, S. AU - Ashihara, E. AU - Kawata, E. AU - Nakagawa, Y. AU - Takeuichi, M. AU - Murotani, Y. AU - Yokota, A. AU - Tanaka, R. PY - 2008 DA - 2008// TI - Anti-myeloma effect of homoharringtonine with concomitant targeting of the myeloma-promoting molecules, mcl-1, XIAP, and beta-catenin JO - Int J Hematol VL - 87 UR - https://doi.org/10.1007/s12185-008-0081-8 DO - 10.1007/s12185-008-0081-8 ID - Kuroda2008 ER - TY - JOUR AU - Kantarjian, H. AU - O'Brien, S. AU - Jabbour, E. AU - Barnes, G. AU - Pathak, A. AU - Cortes, J. PY - 2015 DA - 2015// TI - Effectiveness of homoharringtonine (omacetaxine mepesuccinate) for treatment of acute myeloid leukemia: a meta-analysis of Chinese studies JO - Clin Lymphoma Myeloma Leuk VL - 15 UR - https://doi.org/10.1016/j.clml.2014.09.011 DO - 10.1016/j.clml.2014.09.011 ID - Kantarjian2015 ER - TY - JOUR AU - Hu, J. AU - Dang, N. AU - Menu, E. AU - De Bruyne, E. AU - Xu, D. AU - Van Camp, B. AU - Van Valckenborgh, E. AU - Vanderkerken, K. PY - 2012 DA - 2012// TI - Activation of ATF4 mediates unwanted mcl-1 accumulation by proteasome inhibition JO - Blood VL - 119 UR - https://doi.org/10.1182/blood-2011-07-366492 DO - 10.1182/blood-2011-07-366492 ID - Hu2012 ER - TY - JOUR AU - Chen, P. AU - Yuan, Q. AU - Yang, H. AU - Wen, X. AU - You, P. AU - Hou, D. AU - Xie, J. AU - Cheng, Y. AU - Huang, H. PY - 2017 DA - 2017// TI - Homoharringtonine enhances bortezomib antimyeloma activity in myeloma cells adhesion to bone marrow stromal cells and in SCID mouse xenografts JO - Leuk Res VL - 57 UR - https://doi.org/10.1016/j.leukres.2017.04.007 DO - 10.1016/j.leukres.2017.04.007 ID - Chen2017 ER - TY - JOUR AU - Nguyen, T. AU - Parker, R. AU - Hawkins, E. AU - Holkova, B. AU - Yazbeck, V. AU - Kolluri, A. AU - Kmieciak, M. AU - Rahmani, M. AU - Grant, S. PY - 2017 DA - 2017// TI - Synergistic interactions between PLK1 and HDAC inhibitors in non-Hodgkin's lymphoma cells occur in vitro and in vivo and proceed through multiple mechanisms JO - Oncotarget VL - 8 UR - https://doi.org/10.18632/oncotarget.15649 DO - 10.18632/oncotarget.15649 ID - Nguyen2017 ER - TY - JOUR AU - Nguyen, T. K. AU - Grant, S. PY - 2014 DA - 2014// TI - Dinaciclib (SCH727965) inhibits the unfolded protein response through a CDK1- and 5-dependent mechanism JO - Mol Cancer Ther VL - 13 UR - https://doi.org/10.1158/1535-7163.MCT-13-0714 DO - 10.1158/1535-7163.MCT-13-0714 ID - Nguyen2014 ER - TY - JOUR AU - Nakajima, W. AU - Sharma, K. AU - Lee, J. Y. AU - Maxim, N. T. AU - Hicks, M. A. AU - Vu, T. T. AU - Luu, A. AU - Yeudall, W. A. AU - Tanaka, N. AU - Harada, H. PY - 2016 DA - 2016// TI - DNA damaging agent-induced apoptosis is regulated by MCL-1 phosphorylation and degradation mediated by the Noxa/MCL-1/CDK2 complex JO - Oncotarget VL - 7 UR - https://doi.org/10.18632/oncotarget.9217 DO - 10.18632/oncotarget.9217 ID - Nakajima2016 ER - TY - JOUR AU - Nguyen, T. AU - Dai, Y. AU - Attkisson, E. AU - Kramer, L. AU - Jordan, N. AU - Nguyen, N. AU - Kolluri, N. AU - Muschen, M. AU - Grant, S. PY - 2011 DA - 2011// TI - HDAC inhibitors potentiate the activity of the BCR/ABL kinase inhibitor KW-2449 in imatinib-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo JO - Clin Can Res VL - 17 UR - https://doi.org/10.1158/1078-0432.CCR-11-0234 DO - 10.1158/1078-0432.CCR-11-0234 ID - Nguyen2011 ER - TY - JOUR AU - Klanova, M. AU - Andera, L. AU - Brazina, J. AU - Svadlenka, J. AU - Benesova, S. AU - Soukup, J. AU - Prukova, D. AU - Vejmelkova, D. AU - Jaksa, R. AU - Helman, K. PY - 2016 DA - 2016// TI - Targeting of BCL2 family proteins with ABT-199 and Homoharringtonine reveals BCL2- and MCL1-dependent subgroups of diffuse large B-cell lymphoma JO - Clin Cancer Res VL - 22 UR - https://doi.org/10.1158/1078-0432.CCR-15-1191 DO - 10.1158/1078-0432.CCR-15-1191 ID - Klanova2016 ER - TY - JOUR AU - Hambley, B. AU - Caimi, P. F. AU - William, B. M. PY - 2016 DA - 2016// TI - Bortezomib for the treatment of mantle cell lymphoma: an update JO - Therapeutic Adv Hematol VL - 7 UR - https://doi.org/10.1177/2040620716648566 DO - 10.1177/2040620716648566 ID - Hambley2016 ER - TY - JOUR AU - Mitra, P. AU - Yang, R. M. AU - Sutton, J. AU - Ramsay, R. G. AU - Gonda, T. J. PY - 2016 DA - 2016// TI - CDK9 inhibitors selectively target estrogen receptor-positive breast cancer cells through combined inhibition of MYB and MCL-1 expression JO - Oncotarget VL - 7 UR - https://doi.org/10.18632/oncotarget.6997 DO - 10.18632/oncotarget.6997 ID - Mitra2016 ER - TY - JOUR AU - Yeh, Y. Y. AU - Chen, R. AU - Hessler, J. AU - Mahoney, E. AU - Lehman, A. M. AU - Heerema, N. A. AU - Grever, M. R. AU - Plunkett, W. AU - Byrd, J. C. AU - Johnson, A. J. PY - 2015 DA - 2015// TI - Up-regulation of CDK9 kinase activity and mcl-1 stability contributes to the acquired resistance to cyclin-dependent kinase inhibitors in leukemia JO - Oncotarget VL - 6 UR - https://doi.org/10.18632/oncotarget.2096 DO - 10.18632/oncotarget.2096 ID - Yeh2015 ER - TY - JOUR AU - Chen, R. AU - Keating, M. J. AU - Gandhi, V. AU - Plunkett, W. PY - 2005 DA - 2005// TI - Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death JO - Blood VL - 106 UR - https://doi.org/10.1182/blood-2005-04-1678 DO - 10.1182/blood-2005-04-1678 ID - Chen2005 ER - TY - JOUR AU - Lucas, D. M. AU - Edwards, R. B. AU - Lozanski, G. AU - West, D. A. AU - Shin, J. D. AU - Vargo, M. A. AU - Davis, M. E. AU - Rozewski, D. M. AU - Johnson, A. J. AU - Su, B. N. PY - 2009 DA - 2009// TI - The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo JO - Blood VL - 113 UR - https://doi.org/10.1182/blood-2008-09-175430 DO - 10.1182/blood-2008-09-175430 ID - Lucas2009 ER - TY - JOUR AU - Tang, R. AU - Faussat, A. M. AU - Majdak, P. AU - Marzac, C. AU - Dubrulle, S. AU - Marjanovic, Z. AU - Legrand, O. AU - Marie, J. P. PY - 2006 DA - 2006// TI - Semisynthetic homoharringtonine induces apoptosis via inhibition of protein synthesis and triggers rapid myeloid cell leukemia-1 down-regulation in myeloid leukemia cells JO - Mol Cancer Ther VL - 5 UR - https://doi.org/10.1158/1535-7163.MCT-05-0164 DO - 10.1158/1535-7163.MCT-05-0164 ID - Tang2006 ER - TY - JOUR AU - Williams, S. A. AU - McConkey, D. J. PY - 2003 DA - 2003// TI - The proteasome inhibitor bortezomib stabilizes a novel active form of p53 in human LNCaP-Pro5 prostate cancer cells JO - Cancer Res VL - 63 ID - Williams2003 ER - TY - JOUR AU - Ding, W. X. AU - Ni, H. M. AU - Chen, X. AU - Yu, J. AU - Zhang, L. AU - Yin, X. M. PY - 2007 DA - 2007// TI - A coordinated action of Bax, PUMA, and p53 promotes MG132-induced mitochondria activation and apoptosis in colon cancer cells JO - Mol Cancer Ther VL - 6 UR - https://doi.org/10.1158/1535-7163.MCT-06-0541 DO - 10.1158/1535-7163.MCT-06-0541 ID - Ding2007 ER - TY - JOUR AU - Baou, M. AU - Kohlhaas, S. L. AU - Butterworth, M. AU - Vogler, M. AU - Dinsdale, D. AU - Walewska, R. AU - Majid, A. AU - Eldering, E. AU - Dyer, M. J. AU - Cohen, G. M. PY - 2010 DA - 2010// TI - Role of NOXA and its ubiquitination in proteasome inhibitor-induced apoptosis in chronic lymphocytic leukemia cells JO - Haematologica VL - 95 UR - https://doi.org/10.3324/haematol.2010.022368 DO - 10.3324/haematol.2010.022368 ID - Baou2010 ER - TY - JOUR AU - Rizzatti, E. G. AU - Mora-Jensen, H. AU - Weniger, M. A. AU - Gibellini, F. AU - Lee, E. AU - Daibata, M. AU - Lai, R. AU - Wiestner, A. PY - 2008 DA - 2008// TI - Noxa mediates bortezomib induced apoptosis in both sensitive and intrinsically resistant mantle cell lymphoma cells and this effect is independent of constitutive activity of the AKT and NF-kappaB pathways JO - Leuk Lymphoma VL - 49 UR - https://doi.org/10.1080/10428190801910912 DO - 10.1080/10428190801910912 ID - Rizzatti2008 ER - TY - JOUR AU - Gomez-Bougie, P. AU - Wuilleme-Toumi, S. AU - Menoret, E. AU - Trichet, V. AU - Robillard, N. AU - Philippe, M. AU - Bataille, R. AU - Amiot, M. PY - 2007 DA - 2007// TI - Noxa up-regulation and mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma JO - Cancer Res VL - 67 UR - https://doi.org/10.1158/0008-5472.CAN-06-4322 DO - 10.1158/0008-5472.CAN-06-4322 ID - Gomez-Bougie2007 ER - TY - JOUR AU - Nakajima, W. AU - Hicks, M. A. AU - Tanaka, N. AU - Krystal, G. W. AU - Harada, H. PY - 2014 DA - 2014// TI - Noxa determines localization and stability of MCL-1 and consequently ABT-737 sensitivity in small cell lung cancer JO - Cell Death Dis VL - 5 UR - https://doi.org/10.1038/cddis.2014.6 DO - 10.1038/cddis.2014.6 ID - Nakajima2014 ER - TY - JOUR AU - Oda, E. AU - Ohki, R. AU - Murasawa, H. AU - Nemoto, J. AU - Shibue, T. AU - Yamashita, T. AU - Tokino, T. AU - Taniguchi, T. AU - Tanaka, N. PY - 2000 DA - 2000// TI - Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis JO - Science VL - 288 UR - https://doi.org/10.1126/science.288.5468.1053 DO - 10.1126/science.288.5468.1053 ID - Oda2000 ER - TY - JOUR AU - Ploner, C. AU - Kofler, R. AU - Villunger, A. PY - 2008 DA - 2008// TI - Noxa: at the tip of the balance between life and death JO - Oncogene VL - 27 UR - https://doi.org/10.1038/onc.2009.46 DO - 10.1038/onc.2009.46 ID - Ploner2008 ER - TY - JOUR AU - Busacca, S. AU - Chacko, A. D. AU - Klabatsa, A. AU - Arthur, K. AU - Sheaff, M. AU - Barbone, D. AU - Mutti, L. AU - Gunasekharan, V. K. AU - Gorski, J. J. AU - El-Tanani, M. PY - 2013 DA - 2013// TI - BAK and NOXA are critical determinants of mitochondrial apoptosis induced by bortezomib in mesothelioma JO - PLoS One VL - 8 UR - https://doi.org/10.1371/journal.pone.0065489 DO - 10.1371/journal.pone.0065489 ID - Busacca2013 ER - TY - JOUR AU - Willis, S. N. AU - Chen, L. AU - Dewson, G. AU - Wei, A. AU - Naik, E. AU - Fletcher, J. I. AU - Adams, J. M. AU - Huang, D. C. PY - 2005 DA - 2005// TI - Proapoptotic Bak is sequestered by mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins JO - Genes Dev VL - 19 UR - https://doi.org/10.1101/gad.1304105 DO - 10.1101/gad.1304105 ID - Willis2005 ER - TY - JOUR AU - Nemunaitis, J. AU - Mita, A. AU - Stephenson, J. AU - Mita, M. M. AU - Sarantopoulos, J. AU - Padmanabhan-Iyer, S. AU - Nanda, N. AU - Gleich, L. AU - Benichou, A. C. AU - Craig, A. PY - 2013 DA - 2013// TI - Pharmacokinetic study of omacetaxine mepesuccinate administered subcutaneously to patients with advanced solid and hematologic tumors JO - Cancer Chemother Pharmacol VL - 71 UR - https://doi.org/10.1007/s00280-012-1963-2 DO - 10.1007/s00280-012-1963-2 ID - Nemunaitis2013 ER -